Please try another search
Aarti Drugs Limited, through its subsidiaries, engages in the manufacturing and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company provides APls in various therapeutic areas, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer’s treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, para toluene sulphonic acid methyl ester, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, sodium para toluene sulfinate, para toluene sulphonyl hydrazide, di-phenyl sulphone, formamide, ammonium sulfate, and calcium fluoride, as well as benzene sulphonic acid sodium salt, benzyl nicotinate, methyl nicotinate, ethyl para toluene sulphonate, N-methyl methane sulfonamide, benzene sulphonamide, 2-phenoxy methane sulphanilide, para toluene sulfonamides, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, and N-methyl methane sulfonamides. In addition, the company’s development products portfolio comprises Itraconazole and Fluconazole for antifungal applications; Dabigatran for use as an anticoagulant; Ticagrelor for cardiovascular diseases; Sitagliptin for use as an antidiabetics; and Alpha Lipoic Acid for application as an antioxidants. Further, it provides contract manufacturing services; and develops dermatology products to address various dermatological conditions, which include dermatitis, psoriasis, acne, and eczema. Aarti Drugs Limited was incorporated in 1984 and is headquartered in Mumbai, India.
Name | Age | Since | Title |
---|---|---|---|
Harshit Manila Savla | 61 | 1987 | Joint MD & Executive Director |
Chandrakant Vallabhaji Gogri | 77 | 2012 | Chairman Emeritus |
Prakash Moreshwar Patil | 76 | 1985 | Chairman, MD, CEO & Head of BR |
Priti Paras Savla | 46 | 2014 | Non-Executive Independent Women Director |
Narendra Jagannath Salvi | 59 | 2020 | Non-Executive Director |
Ankit Vikram Paleja | - | 2021 | Independent Director |
Rashesh Chandrakant Gogri | 49 | 2012 | MD & Executive Director |
Uday Moreshwar Patil | 60 | 2000 | Whole-Time Director |
Harit Pragji Shah | 60 | 1995 | Whole-Time Director |
Neha Rajen Gada | 48 | 2022 | Independent Director |
Hasmukh Bhavanji Dedhia | - | 2024 | Additional Independent Director |
Bhaskar Narayan Thorat | 59 | 2022 | Independent Director |
Ajit Eledath Venugopalan | - | 2024 | Additional Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review